Amalgamated Bank Increases Stake in Axon Enterprise, Inc $AXON

Amalgamated Bank increased its holdings in shares of Axon Enterprise, Inc (NASDAQ:AXON) by 5.9% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 16,337 shares of the biotechnology company’s stock after buying an additional 908 shares during the period. Amalgamated Bank’s holdings in Axon Enterprise were worth $13,526,000 at the end of the most recent quarter.

Several other large investors have also recently added to or reduced their stakes in the business. CVA Family Office LLC increased its stake in Axon Enterprise by 26.9% during the 2nd quarter. CVA Family Office LLC now owns 66 shares of the biotechnology company’s stock worth $55,000 after buying an additional 14 shares during the period. LaSalle St. Investment Advisors LLC grew its holdings in Axon Enterprise by 2.1% during the 1st quarter. LaSalle St. Investment Advisors LLC now owns 777 shares of the biotechnology company’s stock worth $408,000 after acquiring an additional 16 shares in the last quarter. Hemington Wealth Management grew its holdings in Axon Enterprise by 70.8% during the 2nd quarter. Hemington Wealth Management now owns 41 shares of the biotechnology company’s stock worth $33,000 after acquiring an additional 17 shares in the last quarter. Washington Trust Advisors Inc. grew its holdings in Axon Enterprise by 44.7% during the 2nd quarter. Washington Trust Advisors Inc. now owns 55 shares of the biotechnology company’s stock worth $46,000 after acquiring an additional 17 shares in the last quarter. Finally, Smartleaf Asset Management LLC grew its holdings in Axon Enterprise by 5.0% during the 1st quarter. Smartleaf Asset Management LLC now owns 379 shares of the biotechnology company’s stock worth $203,000 after acquiring an additional 18 shares in the last quarter. 79.08% of the stock is owned by hedge funds and other institutional investors.

Axon Enterprise Stock Down 2.7%

Shares of NASDAQ AXON opened at $738.88 on Friday. The company has a quick ratio of 2.71, a current ratio of 2.95 and a debt-to-equity ratio of 0.63. Axon Enterprise, Inc has a 52 week low of $422.38 and a 52 week high of $885.91. The firm has a 50-day moving average price of $731.73 and a 200 day moving average price of $730.58. The stock has a market capitalization of $58.01 billion, a price-to-earnings ratio of 182.44, a price-to-earnings-growth ratio of 29.49 and a beta of 1.41.

Axon Enterprise (NASDAQ:AXON) last announced its quarterly earnings data on Monday, August 4th. The biotechnology company reported $2.12 EPS for the quarter, beating the consensus estimate of $1.54 by $0.58. Axon Enterprise had a net margin of 13.64% and a return on equity of 6.80%. The firm had revenue of $668.54 million during the quarter, compared to analysts’ expectations of $641.77 million. During the same quarter last year, the business earned $1.20 earnings per share. The business’s revenue for the quarter was up 32.6% compared to the same quarter last year. Axon Enterprise has set its FY 2025 guidance at EPS. Equities research analysts anticipate that Axon Enterprise, Inc will post 5.8 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms have commented on AXON. Craig Hallum upgraded shares of Axon Enterprise from a “hold” rating to a “buy” rating and set a $900.00 price target for the company in a report on Tuesday, August 5th. JPMorgan Chase & Co. boosted their price target on shares of Axon Enterprise from $730.00 to $850.00 and gave the stock an “overweight” rating in a report on Thursday, July 17th. Morgan Stanley set a $885.00 price target on shares of Axon Enterprise and gave the stock an “overweight” rating in a report on Friday, July 11th. UBS Group reiterated a “neutral” rating and set a $840.00 price target (up previously from $820.00) on shares of Axon Enterprise in a report on Tuesday, August 5th. Finally, Wolfe Research started coverage on shares of Axon Enterprise in a research note on Monday, July 7th. They issued an “outperform” rating on the stock. Fourteen analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $841.64.

Insider Transactions at Axon Enterprise

In related news, CFO Brittany Bagley sold 5,000 shares of the firm’s stock in a transaction dated Monday, September 29th. The shares were sold at an average price of $713.88, for a total value of $3,569,400.00. Following the completion of the sale, the chief financial officer owned 93,592 shares in the company, valued at $66,813,456.96. This trade represents a 5.07% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Patrick W. Smith sold 10,000 shares of the firm’s stock in a transaction on Tuesday, October 7th. The shares were sold at an average price of $713.74, for a total value of $7,137,400.00. Following the completion of the transaction, the chief executive officer owned 3,033,982 shares of the company’s stock, valued at approximately $2,165,474,312.68. This represents a 0.33% decrease in their position. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 59,932 shares of company stock valued at $45,115,616. 4.40% of the stock is owned by company insiders.

Axon Enterprise Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.